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its prevention and management. Hence, other than 
presenting the role of DM in ESRD and the preventive 
choices, this paper was designed to review the glucose 
metabolism and management of hyperglycemia in these 
patients.
IMPACT OF DIABETES MELLITUS AND RENAL 
FAILURE ON EACH OTHER
DM is a metabolic disease that causes renal failure, and 
renal failure increases the need for insulin in diabetic 
patients.[4,20-31] The accumulation of uremic toxins and 
increased parathyroid hormone levels in patients with 
chronic renal failure (CRF) cause insulin resistance 
in tissues, particularly skeletal muscle tissues. This 
has been attributed to damage in the process after 
insulin binding to its receptors, which disturbs glucose 
metabolism and glycogen production.[20,21,24,27,30] It also 
seems that anemia caused by CRF has an impact on 
insulin resistance, and the correction of anemia by 
erythropoietin has been shown to increase insulin 
sensitivity in the body.[32]
INTRODUCTION
End-stage renal disease (ESRD) is a condition in which 
the kidneys are no longer able to work properly in 
response to the needs of day-to-day life. ESRD usually 
occurs following chronic kidney disease and is one of the 
most important and life-threatening diseases. It imposes 
a huge mental and economic burden on societies.[1-18]
Nowadays, diabetes and hypertension have become 
the most common causes of ESRD in both developed 
and developing societies.[4,5,19] In a study conducted in 
the USA, diabetes and hypertension were responsible 
for more than 50% of cases of ESRD,[19] and in a study 
conducted in Khuzestan, Iran, diabetes was the most 
common cause of disease and glomerulonephritis was 
responsible for about 10% of cases.[4]
According to the high prevalence of DM among patients 
with ESRD, there is a huge need to learn more about 
Nowadays, diabetes mellitus (DM) and hypertension are considered as the most common causes of end-stage renal disease (ESRD). 
In this paper, other than presenting the role of DM in ESRD, glucose metabolism and the management of hyperglycemia in these 
patients are reviewed. Although in several large studies there was no significant relationship found between tight glycemic control and 
the survival of ESRD patients, it is recommended that glycemic control be considered as the main therapeutic goal in the treatment 
of these patients to prevent damage to other organs. Glycemic control is perfect when fasting blood sugar is less than 140 mg/dL, 
1-h postprandial blood glucose is less than 200 mg/dL, and glycosylated hemoglobin (HbA1c) is 6-7 in patients with type 1 diabetes 
and 7-8 in patients with type 2 diabetes. Administration of metformin should be avoided in chronic renal failure (CRF) because of 
lactic acidosis, the potentially fatal complication of metformin, but glipizide and repaglinide seem to be good choices.
Key words: Chronic kidney disease, diabetes mellitus (DM), World Kidney Day
Address for correspondence: Prof. Mahmoud Rafieian-Kopaei, Medical Plants Research Center, Shahrekord University of Medical Sciences, 
Shahrekord, Iran. E-mail: rafieian@skums.ac.ir
Received: 13-04-2015; Revised: 14-09-2015; Accepted: 20-11-2015
This is an open access article distributed under the terms of the 
Creative Commons Attribution-NonCommercial-ShareAlike 3.0 
License, which allows others to remix, tweak, and build upon 
the work non-commercially, as long as the author is credited 
and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com
Access this article online
Quick Response Code:
Website:  
www.jmsjournal.net
DOI:  
****
How to cite this article: Nasri H, Rafieian-Kopaei M. Diabetes mellitus and renal failure: Prevention and management. J Res Med Sci 2015;20:1112-20.
R
e
v
ie
w
 A
R
t
ic
l
e
Nasri and Rafieian-Kopaei: Diabetes mellitus and renal failure
Journal of Research in Medical Sciences | November 2015 |1113
Insulin secretion is also reduced in patients with CRF, which 
appears to be due to metabolic acidosis, elevated levels of 
parathyroid hormone, and decreased level of vitamin D.[33,34]
It should be noted that despite the decreased insulin 
secretion and impaired tissue sensitivity to insulin that 
occurs in patients with CRF, most nondiabetic CRF patients 
do not have hyperglycemia unless they are genetically 
predisposed.[20,24]
In advanced stages of CRF, when the glomerular filtration 
rate (GFR) become less than 15-20 cc/min, degradation 
and renal clearance of insulin decreases, which is 
clinically important in the treatment of patients with 
diabetes.[20] Although insulin resistance increases the insulin 
requirement, decreased insulin degradation reduces the 
need for administration of insulin in diabetic patients with 
advanced CRF or even resolves it in patients with type 
2 diabetes. This may increase the risk of hypoglycemia. 
Renal replacement therapy, hemodialysis, and peritoneal 
dialysis relatively resolve this problem in most patients and 
based on the amount of clinical improvement, the insulin 
requirements change. Increased appetite and food intake 
resulting from the replacement therapy and alleviation of 
uremic symptoms also change insulin requirements.[24]
IMPACT OF OXIDATIVE STRESS ON DIABETES 
MELLITUS AND RENAL FAILURE
Under stressful conditions, reactive oxygen species (ROS) 
are overproduced, inducing oxidative stress. Hence, 
oxidative stress is due to an imbalance between free 
radical formation and antioxidant defense capacity.[35-41] 
The result of this oxidative stress would be the induction 
of chronic hard-to-cure diseases such as diabetes,[42-47] 
hypertension,[48,49] cardiovascular disorders,[50-52] cancer,[53-60] 
cognitive diseases,[61-64] and pain,[65-69] or exacerbation of 
some other diseases such as infectious disorders.[70-79]
Oxidative stress also plays a crucial role in the development 
of diabetic kidney disease.[80-85] The number of patients with 
diabetic kidney disease is increasing worldwide. Increase 
in the level of ROS, which induces oxidative stress, has 
been considered the major cause of renal failure. Other 
than diabetes, renal failure itself also increases oxidative 
stress.[86] There are a number of macromolecules that have 
been shown to be implicated in the increased generation 
of ROS, including specific defects in the polyol pathway, 
glycolysis, advanced glycation, xanthine oxidase, reduced 
nicotinamide adenine dinucleotide phosphate [NAD(P)
H] oxidase, and uncoupling of nitric oxide synthase, 
which are the contributors of diabetic kidney disease. 
The morphologic characteristics of diabetic nephropathy 
include tubular atrophy, glomerular hypertrophy, arteriolar 
thickening, basement membrane thickening, mesangial 
expansion, and interstitial fibrosis, which are among the 
microvascular complications of diabetes.[87]
The increase in ROS is due to both increased production 
and decreased and/or inadequate antioxidant availability or 
function. Recent research studies have determined that both 
high glucose-induced changes in antioxidant function and 
high glucose-induced cellular ROS production contribute 
to the diabetes induction of renal failure. Treatments that 
target one or more diabetes-induced alterations for the 
regulation of ROS might lead to effective protection against 
or treatment of diabetic kidney disease. In this regard, the 
use of antioxidants seems to be effective in diabetes and 
protection against kidney disease.[88-90]
ROLE OF ANTIOXIDANTS IN CONTROL OF DIABETES 
AND KIDNEY DISEASE
Buffering the generation of ROS or consumption of these 
compounds might be a promising therapeutic approach to 
ameliorate diabetes and/or renal damage.[90-93]
Antioxidants have been shown to be effective in a lot of ROS-
induced diseases.[94-105] The role of antioxidant therapy in 
diabetes and/or renal failure in humans is not clear, but there 
are a number of preclinical reports showing the effectiveness 
of antioxidants in the prevention and treatment[106-113] of 
diabetes[13,109,114-116] as well as renal failure.[117]
Antioxidants with plant origins have been shown to be a 
better choice for this purpose and a lot of plants exhibit 
antioxidant activity. In this regard, it is better that we try 
using plants that have shown good results for controlling 
both DM and kidney disease.[118-123]
NEW APPROACHES FOR CONTROL OF RENAL 
FAILURE
Control of diabetes and early treatment for the risk 
factors of diabetes are very important in preventing or 
delaying nephropathy. Control of hypertension with 
medications that modulate the renin-angiotensin system 
(RAS) has been shown to decrease the incidence as well as 
progression of diabetic kidney disease.[122] The consumption 
of angiotensin-converting enzyme inhibitors (ACEIs) or 
angiotensin II receptor antagonists reduces the incidence 
of ESRD in patients with type II DM.[122] Interestingly, the 
effects of angiotensin II receptor antagonists and ACEIs 
are independent of any antihypertensive property, which 
suggests a direct renal effect.
Furthermore, several new approaches, including the 
consumption of antifibrotic agents, endothelin receptor 
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antagonists, inhibitors of advanced glycation end-products 
(AGEs), receptor antagonists of advanced glycation end-
products; growth factors and protein kinase C; oxidase 
inhibitors; NADPH; and glycosaminoglycans has shown 
promising results in preventing the progression of diabetic 
nephropathy.[123]
IMPORTANCE OF BLOOD GLUCOSE CONTROL IN 
RENAL FAILURE PATIENTS
Although the importance of tight glycemic control has been 
noted in several small studies,[124] large studies found no 
significant relationship between tight glycemic control and 
survival of dialysis patients. Moreover, tight control of blood 
glucose may increase the risk of hypoglycemic attacks.[125,126] 
According to studies, tight monitoring of blood glucose 
seems to be less important in diabetic dialysis patients than in 
those without renal failure because of the following reasons:
1. Tight glycemic control increases the risk of hypoglycemia in 
dialysis patients, especially patients with reduced appetite;
2. Symptoms of hyperglycemia in dialysis patients are less 
than those in patients without kidney failure. Despite 
these evidences, some researchers suggest that damage 
to organs such as the eyes and heart will increase if blood 
sugar levels do not stay within an acceptable range.
Therefore, based on the recent scientific evidence, it is 
recommended that glycemic control be considered as the 
main therapeutic goal in the treatment of diabetic patients 
with ESRD, too.[127]
Monitoring of blood glucose level in patients with ESRD is 
also important because a significant percentage of dialysis 
patients may get diabetes after the initiation of dialysis. 
Therefore, monitoring of blood glucose levels will help 
in early detection. This should be even more serious for 
patients with peritoneal dialysis because of their exposure to 
high glucose concentrations during peritoneal dialysis. For 
example, in a study conducted on 252 nondiabetic patients 
who received peritoneal dialysis, after 1 month the blood 
sugar level in 8% of them was higher than 200 mg/dL. This 
study also showed an inverse relationship between 3-year 
survival of patients and poorly controlled blood sugar.[128]
According to the studies, if patients with type 2 diabetes 
have a fasting blood sugar less than 120 and glycosylated 
hemoglobin (HbA1c) of 5.6-7%, adequate control of glucose 
levels is required.[129]
METABOLISM OF HYPERGLYCEMIC MEDICATIONS 
IN ESRD PATIENTS
In addition to insulin required for the treatment of diabetes, 
there are many types of oral medications available. Thus, it 
is essential to know the metabolism of these drugs in ESRD 
patients, and they are briefly discussed below.
Sulfonylureas
Sulfonylureas, which are widely used to treat type 2 diabetes, 
stimulate insulin secretion from pancreatic beta cells. These 
drugs inhibit the adenosine triphosphate (ATP)-dependent 
channels by binding to their receptors in pancreatic beta cells, 
leading to calcium influx and stimulation of insulin secretion. 
Thus, sulfonylureas are only effective in diabetic patients with 
some remaining beta cell function. These drugs have been 
reported to increase tissue sensitivity to insulin, but the clinical 
importance of this effect is negligible. Sulfonylureas usually 
lower blood glucose levels by 20% and HbA1c levels by 1.5-2%. 
These drugs are usually used in patients whose weight is normal 
or slightly increased. These drugs should not be used in patients 
who are losing weight, or are ketotic despite adequate caloric 
intake. In these cases, insulin should be used.[130,131]
Today, second-generation sulfonylureas including 
glibenclamide, gliclazide, glipizide, and glimepiride 
have largely replaced with the first generation including 
chlorpropamide, tolazamide, and tolbutamide.
Chlorpropamide and tolbutamide are substantially excreted 
by the kidney in patients with normal renal function, 
but in patients with chronic kidney disease, the elevated 
serum levels caused by these drugs may cause severe 
hypoglycemia. Active metabolites of glibenclamide are 
also excreted by the kidney and increased serum levels 
caused by them have been observed in patients with renal 
failure.[56,61-63] Although glimepiride is metabolized by the 
liver, its active metabolites are excreted by the kidneys. 
Glimepiride is similar to glibenclamide in this aspect.[132]
Although glipizide is metabolized in the liver, its inactive 
metabolites are renally excreted. Therefore, glipizide is 
considered the oral hypoglycemic drug of choice from this 
group of drugs for patients with CRF. It is recommended 
that drug dosage should be reduced to approximately 50% 
if the GFR is less than 50 cc/min. The recommended initial 
dose for patients with normal renal function is 2.5-5 mg per 
day and the maximum dose is 20-40 mg per day in some 
references. The recommended dose for patients with renal 
failure is 2.5-10 mg per day.[133]
A low dose of glibenclamide can be given to patients with 
a GFR above 50 cc/min, but it should be avoided entirely 
in patients with acute renal failure.[133,134]
It should be noted that some drugs such as beta blockers, 
salicylates, and warfarin can separate sulfonylureas from 
the bonded proteins, which increases the amount of these 
drugs in blood; thus their glucose-lowering effects.[135]
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Biguanides
The only available drug in the biguanides class is metformin. 
Biguanides reduce glucose production and release by the 
liver, increase insulin-stimulated glucose uptake by all 
peripheral tissues such as muscles, and decrease plasma 
levels of free fatty acids, and thus gluconeogenesis.
Like sulfonylureas, metformin typically reduces fasting 
plasma glucose levels by 20% and HbA1C by 1.5%. The 
most common side effects of metformin are gastrointestinal 
disorders, including a metallic taste in the mouth, mild 
anorexia, nausea, and diarrhea, which cause treatment to 
be discontinued in 5% of cases. The most serious side effect 
of metformin is lactic acidosis, which happens rarely.[136,137]
The important factors that affect these complications are 
kidney, liver, and heart failures and kidney failure is the 
most important of them. This drug is usually excreted 
unchanged by the kidney, and its administration to patients 
with renal failure can cause drug retention and lactic 
acidosis. It is recommended to be avoided when GFR is 
less than 60 cc/min or serum creatinine is greater than 5.1 
for men and 4.1 for women.[138-140]
Thiozolidindiones
Thiazolidinediones improve insulin sensitivity by 
increasing glucose utilization in the liver, skeletal muscle, 
and adipose tissues; suppress hepatic production of glucose 
through binding to peroxisome proliferator-activated 
receptors (PPARs); and increase insulin secretion through 
improvement of pancreatic beta cell function.[132,134]
Rosiglitazone and pioglitazone, the two main drugs of the 
thiazolidinedione family display strong protein-binding 
capacity, especially for albumin. Both these drugs and their 
metabolites are not retained in kidney failure; however, they 
can cause heart failure in patients receiving insulin.[132,133]
In a study, rosiglitazone increased mortality from 
cardiovascular diseases in dialysis patients. The 
administration of these drugs should be avoided in patients 
with ESRD, especially if they also have heart failure.[141]
Alpha-glucosidase inhibitors
The alpha-glucosidase inhibitors such as acarbose and 
miglitol reduce postprandial hyperglycemia by delaying 
the absorption of carbohydrate from the small intestine. 
The plasma levels of acarbose and its metabolites increase 
in patients with renal failure, but their relationship with an 
increased risk of hypoglycemia has not been established. 
Miglitol is also significantly excreted by the kidneys and 
expected to increase in the serum of patients with renal 
failure, so their administration is not recommended in 
patients with renal insufficiency.[134]
Meglitinides
Nateglinide and repaglinide are relatively new drugs in the 
meglitinides class that are used to treat diabetes. They are 
short-acting blood glucose-lowering medicines. Although 
their structural features and receptors are different from 
sulfonylurea, they also increase insulin secretion from 
pancreatic beta cells through ATP-dependent potassium 
channels.[134]
The recommended dose of repaglinide for people with 
normal renal function who have not previously received 
blood glucose-lowering agents is 50 mg before meals and the 
maximum dose is 40 mg before every meal. The suggested 
dose of nateglinide is 120 mg before every meal.
Although nateglinide is metabolized by the liver, its active 
metabolites are excreted by the kidney. In renal failure, 
active metabolites accumulate and cause hypoglycemia, 
so this drug should be used carefully or not prescribed in 
patients with renal failure.[142,143]
Repaglinide is also metabolized by the liver, but less 
than 10% of its metabolites are eliminated renally. Thus 
its use may be allowed in patients with ESRD.[89] A study 
showed that the risk of hypoglycemia for patients with 
ESRD receiving this drug was higher than that for patients 
with normal renal functions. Therefore the recommended 
starting dose of this drug for patients with renal failure 
is 0.5 mg per day and it should be increased carefully if a 
higher dose is required.[144]
Insulin
The renal and hepatic metabolism of insulin is decreased 
in CRF, so its recommended dose should be reduced in the 
following manner:[133,134]
When the GFR is above 50 mL/min, no dose reduction is 
required When the GFR is 10-50 mL/min, the insulin dose 
should be reduced to approximately 75%. When the GFR 
is less than 10-50 mL/min, the dose should be reduced to 
approximately 50%. These adjustments are general, and 
insulin dosage adjustments should be based on regular 
blood glucose measurements. It should be noted that 
correction of uremia with dialysis on the one hand reduces 
insulin resistance and on the other hand increases insulin 
degradation; the ultimate effect of these on glycemic control 
in patients is different and glycemic control should be based 
on the final effect.[118,145-161]
CONCLUSION
In early stages of renal failure, insulin secretion and 
resistance in peripheral tissues, primarily in skeletal muscle, 
is reduced, and in advanced stages of renal failure, renal 
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clearance is reduced. These facts are clinically important 
in the treatment of diabetes. Although insulin resistance 
increases the insulin requirement, decreased insulin 
degradation reduces the need for administration of insulin 
in diabetic patients with advanced CRF, which increases the 
risk of hypoglycemia.
Severe hyperglycemia in oliguric or anuric ESRD patients 
is not associated with features of osmotic diuresis, which 
is seen in patients without renal failure, but it can cause 
hyponatremia, hyperkalemia, and acute increase in the 
intravascular volume.
In several large studies on ESRD patients, there was no 
correlation between increased survival and tight blood 
glucose control of patients. It is suggested that the incidence 
of hypoglycemia was significantly higher in patients receiving 
strict glycemic control. It is recommended that blood sugar 
control be considered an important goal in the treatment of 
ESRD diabetic patients to prevent additional damage to other 
organs including the eyes, kidneys, and heart.
The factors determining perfect glycemic control are the 
following: Fasting blood sugar less than 126 mg/dL, 1-h 
postprandial blood glucose less than 200 mg/dL, and HbA1c 
7-6 in patients with type 1 diabetes and 7-8 in patients with 
type 2 diabetes.
Glipizide, an oral hypoglycemic agent, is administered at 
a daily dose of 2.5-10 mg in patients with CRF. Although 
thiazolidines and their metabolites are not retained in 
kidney failure, they can lead to edema and cardiac failure, 
particularly in patients receiving insulin. Hence their use 
has been prohibited in patients with advanced renal failure, 
particularly if they also have heart failure. Repaglinide is 
mainly metabolized by the liver, and less than 10% of its 
metabolites are excreted by the kidneys. Thus its use in 
ESRD patients may be allowed with meticulous care and 
with regard to the risk of hypoglycemia. Lactic acidosis is 
a rare but potentially fatal complication of metformin, so 
the administration of this drug should also be avoided in 
CRF patients. Insulin can be administered subcutaneously 
or intraperitoneally in patients on peritoneal dialysis with 
safety and accurate monitoring. DM induces renal failure, 
which increases oxidative stress and oxidative aggravate 
them. Therefore, the use of antioxidants, especially the 
ones which are effective in treating these two diseases,[118-123] 
should be beneficial.
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